These findings collectively establish HIF-1α pathway targeting as a viable strategy to subvert CLL cell survival mechanisms, offering significant potential for improving clinical outcomes in CLL patients. This evidence concerns the gene HIF1A and B-cell chronic lymphocytic leukemia.